This Article Full Text Full Text (PDF) Data Supplement Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Mehta, S. R. Search for Related Content PubMed PubMed Citation Articles by Mehta, S. R. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Medline Plus Health Information Angioplasty Blood Thinners Hazardous Substances DB HEPARIN Related Collections Anticoagulant mechanisms Arterial thrombosis Coagulation Thrombin Heparin Other anticoagulants Catheter-based coronary and valvular interventions: other Catheter-based coronary interventions: stents Acute coronary syndromes

(Circulation. 2005;111:1390-1397.)
© 2005 American Heart Association, Inc.

Interventional Cardiology

Randomized, Blinded Trial Comparing Fondaparinux With Unfractionated Heparin in Patients Undergoing Contemporary Percutaneous Coronary Intervention

Arixtra Study in Percutaneous Coronary Intervention: A Randomized Evaluation (ASPIRE) Pilot Trial

Shamir R. Mehta, MD, MSc; Philippe Gabriel Steg, MD; Christopher B. Granger, MD; Jean-Pierre Bassand, MD; David P. Faxon, MD; Jeffrey I. Weitz, MD; Rizwan Afzal, MSc; Bonnie Rush; Ron J.G. Peters, MD; Madhu K. Natarajan, MD; James L. Velianou, MD; David M. Goodhart, MD; Marino Labinaz, MD; Jean-Francois Tanguay, MD; Keith A.A. Fox, MBChB; Salim Yusuf, DPhil, for the ASPIRE Investigators^*

From McMaster University and the Population Health Research Institute (S.R.M., J.L.W., R.A., B.R., M.K.N., J.L.V., S.Y.), Hamilton Health Sciences, Hamilton, Canada; Hôpital Bichat (P.G.S.), Paris, France; Duke Clinical Research Institute (C.B.G.), Durham, NC; Centre Hospitalier Universitaire Jean Minjoz (J.-P.B.), Besancon, France; University of Chicago (D.P.F.), Chicago, Ill; Academic Medical Center (R.J.G.P.), Amsterdam, the Netherlands; Foothills Medical Center (D.M.G.), Calgary, Canada; Ottawa Heart Institute (M.L.), Ottawa, Canada; Montreal Heart Institute (J.-F.T.), Montreal, Canada; and the Royal Infirmary (K.A.A.F.), Edinburgh, Scotland.

Correspondence to Dr Shamir R. Mehta, Interventional Cardiology, Hamilton Health Sciences, General Division, 237 Barton St E, Hamilton, Ontario, Canada L6K 1B8. E-mail smehta{at}mcmaster.ca

Received July 19, 2004; revision received December 13, 2004; accepted December 21, 2004.

Background— Factor Xa plays a central role in the generation of thrombin, making it a novel target for treatment of arterial thrombosis. Fondaparinux is a synthetic factor Xa inhibitor that has been shown to be superior to standard therapies for the prevention of venous thrombosis. We performed a randomized trial to determine the safety and feasibility of fondaparinux in the percutaneous coronary intervention (PCI) setting.

Methods and Results— A total of 350 patients undergoing elective or urgent PCI were randomized in a blinded manner to receive unfractionated heparin (UFH), 2.5 mg fondaparinux IV, or 5.0 mg fondaparinux IV. Randomization was stratified for planned or no planned use of glycoprotein (GP) IIb/IIIa antagonists. The primary safety outcome was total bleeding, which was a combination of major and minor bleeding events. The incidence of total bleeding was 7.7% in the UFH group and 6.4% in the combined fondaparinux groups (hazard ratio, 0.81; 95% confidence interval, 0.35 to 1.84; P=0.61). Bleeding was less common in the 2.5-mg fondaparinux group compared with the 5-mg fondaparinux group (3.4% versus 9.6%, P=0.06). The composite efficacy outcome of all-cause mortality, myocardial infarction, urgent revascularization, or need for a bailout GPIIb/IIIa antagonist was 6.0% in the UFH group and 6.0% in the fondaparinux group, with no significant difference in efficacy among the fondaparinux doses compared with UFH. Coagulation marker analysis at 6 and 12 hours after PCI demonstrated that fondaparinux was superior to UFH in inducing a sustained reduction in markers of thrombin generation, as measured by prothrombin fragment F1.2 (P=0.02).

Conclusions— In this pilot study of patients undergoing contemporary PCI, factor Xa inhibition with the synthetic anticoagulant fondaparinux in doses of 2.5 and 5.0 mg was comparable to UFH for clinical safety and efficacy outcomes. These data form the basis for further evaluation of fondaparinux in arterial thrombosis.

Key Words: angioplasty • stents • anticoagulants • complications

This article has been cited by other articles:

				R. A. Harrington, R. C. Becker, C. P. Cannon, D. Gutterman, A. M. Lincoff, J. J. Popma, G. Steg, G. H. Guyatt, and S. G. Goodman Antithrombotic Therapy for Non-ST-Segment Elevation Acute Coronary Syndromes: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition) Chest, June 1, 2008; 133(6_suppl): 670S - 707S. [Abstract] [Full Text] [PDF]

				A. G.G. Turpie Selective factor Xa inhibition with fondaparinux: from concept to clinical benefit Eur. Heart J. Suppl., April 1, 2008; 10(suppl_C): C1 - C7. [Abstract] [Full Text] [PDF]

				R. Dumaine, M. Borentain, O. Bertel, C. Bode, R. Gallo, H. D. White, J.-P. Collet, S. R. Steinhubl, and G. Montalescot Intravenous Low-Molecular-Weight Heparins Compared With Unfractionated Heparin in Percutaneous Coronary Intervention: Quantitative Review of Randomized Trials Arch Intern Med, December 10, 2007; 167(22): 2423 - 2430. [Abstract] [Full Text] [PDF]

				Authors/Task Force Members, J.-P. Bassand, C. W. Hamm, D. Ardissino, E. Boersma, A. Budaj, F. Fernandez-Aviles, K. A.A. Fox, D. Hasdai, E. M. Ohman, et al. Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes: The Task Force for the Diagnosis and Treatment of Non-ST-Segment Elevation Acute Coronary Syndromes of the European Society of Cardiology Eur. Heart J., July 1, 2007; 28(13): 1598 - 1660. [Full Text] [PDF]

				M. Cohen, D. L. Bhatt, J. H. Alexander, G. Montalescot, C. Bode, T. Henry, J.-F. Tamby, J. Saaiman, S. Simek, J. De Swart, et al. Randomized, Double-Blind, Dose-Ranging Study of Otamixaban, a Novel, Parenteral, Short-Acting Direct Factor Xa Inhibitor, in Percutaneous Coronary Intervention: The SEPIA-PCI Trial Circulation, May 22, 2007; 115(20): 2642 - 2651. [Abstract] [Full Text] [PDF]

				R. De Caterina, S. Husted, L. Wallentin, G. Agnelli, F. Bachmann, C. Baigent, J. Jespersen, S. D. Kristensen, G. Montalescot, A. Siegbahn, et al. Anticoagulants in heart disease: current status and perspectives Eur. Heart J., April 10, 2007; (2007) ehl492v1. [Full Text] [PDF]

				W. W. O'Neill Risk of bleeding after elective percutaneous coronary intervention. N. Engl. J. Med., September 7, 2006; 355(10): 1058 - 1060. [Full Text] [PDF]

				S. R. Dixon, C. L. Grines, and W. W. O'Neill The Year in Interventional Cardiology J. Am. Coll. Cardiol., April 18, 2006; 47(8): 1689 - 1706. [Full Text] [PDF]

				The Fifth Organization to Assess Strategies in Acu Comparison of Fondaparinux and Enoxaparin in Acute Coronary Syndromes N. Engl. J. Med., April 6, 2006; 354(14): 1464 - 1476. [Abstract] [Full Text] [PDF]

				R. P. Giugliano and E. Braunwald The Year in Non--ST-Segment Elevation Acute Coronary Syndromes J. Am. Coll. Cardiol., September 6, 2005; 46(5): 906 - 919. [Full Text] [PDF]